SNCA and neurodegenerative disease: In vitro models using adenoviral overexpression of alpha synuclein in dopaminergic neurons and the in vivo model of P301S tau transgenic mice will allow for refined protocols of siRNA application and thus testing the effect of synuclein or tau knock-down as new therapeutic approaches in neurodegenerative diseases.